Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Care | Research

Cardiovascular events and mortality in chronic kidney disease in primary care patients with previous type 2 diabetes and/or hypertension. A population-based epidemiological study (KIDNEES)

Authors: Oriol Cunillera-Puértolas, David Vizcaya, M. Jesús Cerain-Herrero, Neus Gil-Terrón, Silvia Cobo-Guerrero, Betlem Salvador-González

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Chronic Kidney Disease (CKD), Type 2 Diabetes (T2D) and Hypertension (HTN) are frequently associated with adverse outcomes. We aimed to estimate the impact of a prior diagnosis of T2D and/or HTN on clinical characteristics, cardiovascular events (CVE) and all-cause mortality (ACM) of patients with CKD.

Methods

We conducted a retrospective cohort study based on primary care electronic health records of people without atherosclerotic cardiovascular disease, aged 18–90 years with incident CKD between January 1, 2007, and December 31, 2017. The association between CKD groups classified according to prior diagnosis of T2D and/or HTN and risk of ACM and CVE at follow-up was evaluated with Cox and Fine-Gray regression models, respectively.

Results

398,477 patients were included. Median age was 74 years and 55.2% were women. Individuals were classified as CKD with HTN (51.9%), CKD with T2D (3.87%), CKD with HTN/T2D (31.4%) and CKD without HTN/T2D (12.9%). In the multivariate analysis, with the CKD without HTN/T2D group as reference, the ACM Hazard Ratio (HR) was 0.74 (95%CI 0.72–0.75) for the CKD with HTN group, 0.81 (95%CI 0.79–0.83) for CKD with HTN/T2D and 1.14 (95%CI 1.10–1.19) for the CKD with T2D group. The sub distribution HRs for CVE were 1.40 (95%CI 1.34–1.47), 1.70 (95%CI 1.61–1.80) and 1.37 (95%CI 1.26–1.48), respectively.

Conclusion

In patients with CKD, the risk of ACM and CVE differed in patients with previous HTN and/or T2D. These comorbidities can help identify individuals at higher risk of adverse outcomes and improve the management of patients with CKD in primary care.
Appendix
Available only for authorised users
Literature
1.
go back to reference Matsushita K, Van der Velde M, Astor B, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRef Matsushita K, Van der Velde M, Astor B, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.CrossRef
2.
go back to reference Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–25.CrossRef Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–25.CrossRef
3.
go back to reference Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.CrossRef Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.CrossRef
4.
go back to reference KDIGO. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl.2013;3:4. KDIGO. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl.2013;3:4.
5.
go back to reference Webster AC, Nagler EV, Morton RL, et al. Chronic Kidney Disease Lancet. 2017;389:1238–52. Webster AC, Nagler EV, Morton RL, et al. Chronic Kidney Disease Lancet. 2017;389:1238–52.
6.
go back to reference De Nicola L, Provenzano M, Chiodini P, et al. Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care. PLoS ONE. 2015;10(5):e0127071.CrossRef De Nicola L, Provenzano M, Chiodini P, et al. Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care. PLoS ONE. 2015;10(5):e0127071.CrossRef
7.
go back to reference Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163(13):1555–65.CrossRef Bakris GL, Weir MR, Shanifar S, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163(13):1555–65.CrossRef
8.
go back to reference Piepoli MF, Abreu A, Albus C, et al. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2020;27(2):181–205.CrossRef Piepoli MF, Abreu A, Albus C, et al. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2020;27(2):181–205.CrossRef
9.
go back to reference Ramos R, Balló E, Marrugat J, et al. Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. Rev Esp Cardiol. 2012;65(1):29–37.CrossRef Ramos R, Balló E, Marrugat J, et al. Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. Rev Esp Cardiol. 2012;65(1):29–37.CrossRef
10.
go back to reference García-Gil M, Hermosilla E, Prieto-Alhambra D, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inf Prim Care. 2011;19(3):135–45. García-Gil M, Hermosilla E, Prieto-Alhambra D, et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). Inf Prim Care. 2011;19(3):135–45.
11.
go back to reference Domínguez-Berjón MF, Borrell C, Cano-Serral G, et al. Constructing a deprivation index based on census data in large Spanish cities (the MEDEA project). Gac Sanit. 2008;22(3):179–87. Domínguez-Berjón MF, Borrell C, Cano-Serral G, et al. Constructing a deprivation index based on census data in large Spanish cities (the MEDEA project). Gac Sanit. 2008;22(3):179–87.
12.
go back to reference von Hippel PT. How Many Imputations Do You Need? A Two-stage Calculation Using a Quadratic Rule. Sociol Methods Res. 2020;49(3):699–718. First published January 18, 2018.CrossRef von Hippel PT. How Many Imputations Do You Need? A Two-stage Calculation Using a Quadratic Rule. Sociol Methods Res. 2020;49(3):699–718. First published January 18, 2018.CrossRef
13.
go back to reference Salinero-Fort MA, San Andrés-Rebollo FJ, de Burgos-Lunar C, et al. Five-Year Incidence of Chronic Kidney Disease (Stage 3–5) and Associated Risk Factors in a Spanish Cohort. PLoS ONE. 2015;10(4):e0122030.CrossRef Salinero-Fort MA, San Andrés-Rebollo FJ, de Burgos-Lunar C, et al. Five-Year Incidence of Chronic Kidney Disease (Stage 3–5) and Associated Risk Factors in a Spanish Cohort. PLoS ONE. 2015;10(4):e0122030.CrossRef
14.
go back to reference Gil-Terrón N, Cerain-Herrero MJ, Subirana I, et al. Cardiovascular risk in mild to moderately decreased glomerular filtration rate, diabetes and coronary heart disease in a southern European region. Rev Esp Cardiol. 2020;73(3):212–8.CrossRef Gil-Terrón N, Cerain-Herrero MJ, Subirana I, et al. Cardiovascular risk in mild to moderately decreased glomerular filtration rate, diabetes and coronary heart disease in a southern European region. Rev Esp Cardiol. 2020;73(3):212–8.CrossRef
15.
go back to reference Griffin KA. Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease. Hypertension. 2017;70(4):687–94.CrossRef Griffin KA. Hypertensive Kidney Injury and the Progression of Chronic Kidney Disease. Hypertension. 2017;70(4):687–94.CrossRef
16.
go back to reference Di Vincenzo A, Bettini S, Russo L, et al. Renal structure in type 2 diabetes: facts and misconceptions. J Nephrol. 2020;33(5):901–7.CrossRef Di Vincenzo A, Bettini S, Russo L, et al. Renal structure in type 2 diabetes: facts and misconceptions. J Nephrol. 2020;33(5):901–7.CrossRef
17.
go back to reference Nichols GA, Déruaz-Luyet A, Brodovicz KG, et al. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrol. 2020;21(1):167.CrossRef Nichols GA, Déruaz-Luyet A, Brodovicz KG, et al. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrol. 2020;21(1):167.CrossRef
18.
go back to reference Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012;380(9854):1649-61. Erratum in: Lancet 2012;380(9854):1648. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012;380(9854):1649-61. Erratum in: Lancet 2012;380(9854):1648.
19.
go back to reference Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011 Apr;26(4):379–85.CrossRef Dalrymple LS, Katz R, Kestenbaum B, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011 Apr;26(4):379–85.CrossRef
20.
go back to reference Minutolo R, Lapi F, Chiodini P, et al. Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study. Clin J Am Soc Nephrol. 2014;9(9):1586–93.CrossRef Minutolo R, Lapi F, Chiodini P, et al. Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study. Clin J Am Soc Nephrol. 2014;9(9):1586–93.CrossRef
21.
go back to reference Tancredi M, Rosengren A, Svensson AM, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373(18):1720–32.CrossRef Tancredi M, Rosengren A, Svensson AM, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015;373(18):1720–32.CrossRef
22.
go back to reference Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295.CrossRef Raghavan S, Vassy JL, Ho YL, et al. Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults. J Am Heart Assoc. 2019;8(4):e011295.CrossRef
23.
go back to reference Evans M, Grams ME, Sang Y, et al. Risk Factors for Prognosis in Patients With Severely Decreased GFR. Kidney Int Rep. 2018;3(3):625–37.CrossRef Evans M, Grams ME, Sang Y, et al. Risk Factors for Prognosis in Patients With Severely Decreased GFR. Kidney Int Rep. 2018;3(3):625–37.CrossRef
24.
go back to reference Currie CJ, Berni ER, Berni TR, et al. Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status. PLoS ONE. 2019;14(8):e0221044.CrossRef Currie CJ, Berni ER, Berni TR, et al. Major adverse cardiovascular events in people with chronic kidney disease in relation to disease severity and diabetes status. PLoS ONE. 2019;14(8):e0221044.CrossRef
25.
go back to reference Tuttle KR, Alicic RZ, Duru OK, et al. Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. JAMA Netw Open. 2019;2(12):e1918169.CrossRef Tuttle KR, Alicic RZ, Duru OK, et al. Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children: An Analysis of the CURE-CKD Registry. JAMA Netw Open. 2019;2(12):e1918169.CrossRef
26.
go back to reference Bello AK, Ronksley PE, Tangri N, et al. Quality of Chronic Kidney Disease Management in Canadian Primary Care. JAMA Netw Open. 2019;2(9):e1910704.CrossRef Bello AK, Ronksley PE, Tangri N, et al. Quality of Chronic Kidney Disease Management in Canadian Primary Care. JAMA Netw Open. 2019;2(9):e1910704.CrossRef
27.
go back to reference Liu P, Quinn RR, Lam NN, et al. Accounting for Age in the Definition of Chronic Kidney Disease. JAMA Intern Med. 2021;181(10):1359–66.CrossRef Liu P, Quinn RR, Lam NN, et al. Accounting for Age in the Definition of Chronic Kidney Disease. JAMA Intern Med. 2021;181(10):1359–66.CrossRef
28.
go back to reference Bansal N, Katz R, Robinson-Cohen C, et al. Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies. JAMA Cardiol. 2017;2(3):314–8.CrossRef Bansal N, Katz R, Robinson-Cohen C, et al. Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies. JAMA Cardiol. 2017;2(3):314–8.CrossRef
Metadata
Title
Cardiovascular events and mortality in chronic kidney disease in primary care patients with previous type 2 diabetes and/or hypertension. A population-based epidemiological study (KIDNEES)
Authors
Oriol Cunillera-Puértolas
David Vizcaya
M. Jesús Cerain-Herrero
Neus Gil-Terrón
Silvia Cobo-Guerrero
Betlem Salvador-González
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-022-02966-6

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.